Citigroup Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $371
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Buy Rating Affirmed for Madrigal Pharmaceuticals on Strong Rezdiffra Sales and Promising Growth Outlook
Madrigal Pharmaceuticals Analyst Ratings
B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating
Underperform Rating on Madrigal Pharmaceuticals Amid Rezdiffra's Commercial and Competitive Challenges
Leerink Partners Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch Prospects
Madrigal Pharmaceuticals Analyst Ratings
JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $385
Madrigal Pharmaceuticals Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Benitec Biopharma (BNTC)
Madrigal Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Centene (CNC), Zimmer Biomet Holdings (ZBH) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Akero Therapeutics (AKRO) and Madrigal Pharmaceuticals (MDGL)
B. Riley Securities: Maintaining the Madrigal Pharmaceuticals (MDGL.US) rating, adjusted from neutral to neutral, and adjusted the target price from $270.00 to $200.00.
Madrigal Pharmaceuticals Analyst Ratings
B. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $200